Welcome to

TARGEDYS

Our mission is to control metabolic disease by modulating the appetite through an intervention on the microbiome.

WHO ARE WE?

OUR UNIQUE APPROACH

Is to use the concept of molecular mimicry to physiologically bind well-described pharmacological targets with bacterial metabolites and derived small molecules

TargEDys® translates its unique understanding of the gut-brain axis to develop and manufacture nutritional and therapeutic solutions to control metabolic diseases. The company aims to be at the forefront of safe and effective weight management to improve the health and life quality of many over and underweight people.

 

The TargEDys research team at the INSERM lab of Rouen University has identified a novel mechanism of appetite regulation involving bacterial, hormonal mimetic, proteins that are found naturally in the gut microbiome. This mechanism acts as the basis of TargEDys’ two technologies: ProbioSatys™ and ProbioNutrys™, which respectively moderate the appetite of overweight people and restore the appetite of elderly, cachexic or anorexic people.

OUR FOCUS

Overweight

1.4B

people (>20yrs) are overweight
(WHO, 2009)

5th

biggest risk factor for death is obesity
(WHO, 2014)

50%

of the population in France are overweight
(INVS, 2016)

70%

of the US population are affected by obesity and overweight
(OECD, 2017)

13%

of the worldwide adult population are obese
(The Lancet, 2016)
Underweight

70M

people worldwide suffering from eating disorders
(Renfrew, 2003)

3rd

most common chronic illness for adolescents is anorexia
(Yeo&Hughes, 2011)

50-80%

of cancer patients
are affected
by cachexia
(Anker, 2014)

20%

of cancer deaths
are caused
by cachexia
(Takabe, 2015)

30-60%

of elderly
people are
undernourished
(Bozzetti, 2010)

OUR TIMELINE

Our

NEWS

Latest company news and where to find us

19th-20th June, 2018, Biocitech Romainville-Grand Paris

Adebiotech

TargEDys CEO, Grégory Lambert will present our innovative ProbioSatys technology at The Adebiotech Conference in June. This conference aims to bring together academic and industrial experts from all sectors of application, prevention and treatment for human and animal health, nutrition whilst focusing on the microbiome.

Read more

23rd May 2018, London

Microbiome Invest Congress

TargEDys has been selected as a finalist for the 'Pitch Your Microbes’ showcase running in London on May 23rd as part of the Microbiome Invest event. This event is dedicated to showcasing the most innovative emerging companies and academics with commercially viable research that manipulates the microbiome.

Read more

20th-21st June 2018, La Rochelle

Journées Aliments & Santé

TargEDys will be attending the 12th edition of the Journées Aliments & Santé in La Rochelle in June. This event is the most important European business convention in the agri-food sector.

Read more

Technology

& HEALTH

Learn more about our technology

ProbioSatys™ ProbioNutrys™

WHAT IS THE MICROBIOME?

The human microbiome is the genome of our microbes. It is 150 times more diverse than our human genome and formed of 5000-different species of bacteria living all over our bodies, especially our gut, mouth and skin. This symbiotic bacterial community is vital for day-to-day bodily functions such as immunity, defence against pathogens, host nutrition, synthesis of vitamins, fat storage and influencing human behaviour. An imbalance in one’s microbiome has been linked to a range of diseases such as Diabetes, Cancer and Obesity. A key step to unlocking the potential of many microbiome based treatments is to fully understand the microbiome and its interactions with the human host.

WHAT IS THE GUT-BRAIN AXIS?

The gut-brain axis is the bidirectional communication between the central and enteric nervous systems, linking the emotional and cognitive centres of the brain with peripheral intestinal functions. Gut microbiota are very important in influencing these interactions. TargEDys® has discovered a new mechanism of appetite regulation that involves this axis and has developed two types of innovative technology for the treatment of over and underweight patients, ProbioSatys™ and ProbioNutrys™ respectively.

HOW DOES THE MICROBIOME REGULATE YOUR APPETITE?

Watch the video

projects PLATFORM

PROBIOSATYS™

Enhancing natural
satiety pathways

After a meal, intestinal bacteria feed on the ingested food and begin to multiply. During this growth phase, the bacteria produce various signals that allow them to interact with the brain. One such signal is the protein ClpB, produced by Enterobacteria naturally present in the intestines. ClpB has been identified as a mimetic of the satiety hormone (α-MSH) that regulates food behaviour at both peripheral and central levels.

When released, ClpB directly stimulates the enteroendocrine L-cells of the intestine to produce satiety hormones. ClpB also enters the bloodstream to act on satiety regulation in the central nervous system by mimicking α-MSH. The resulting effect is the feeling of satiety or fullness after a meal.

KEY BENEFITS

The basis of the ProbioSatys™ technology is an Enterobacteria probiotic strain that produces satiety protein, ClpB.

• Decrease of body weight gain
• Decrease of food intake
• Improvement of body composition
• Activation of lipolysis
• Activation of central satiety pathways

PROBIONUTRYS™

TargEDys is currently demonstrating the efficacy of another hormone mimetic technology that exploits the gut-brain axis to improve the appetite of anorexic, cachexic or elderly patients.

Publications &

PRESS

Here are our latest peer reviewed publications, press releases and press articles.

Nature Reviews Endocrinology (2017)

Fetissov, Serguei O.

Role of the Gut Microbiota in Host Appetite Control:
Bacterial Growth to Animal Feeding Behaviour

The life of all animals is dominated by alternating feelings of hunger and satiety — the main involuntary motivations for feeding-related behaviour. Gut bacteria depend fully on their host for providing the nutrients necessary for their growth. […] This Review analyses the data relevant to possible involvement of the gut bacteria in the regulation of host appetite and proposes an integrative homeostatic model of appetite control that includes energy needs of both the host and its gut bacteria.

Read more

THE INTERNATIONAL JOURNAL OF EATING DISORDERS (2016).

Breton J., R. Legrand et al.

« Elevated Plasma Concentrations of Bacterial ClpB Protein in Patients with Eating Disorders ».

Read more

CELL METABOLISM (2016).

Breton, J. et al.

« Gut Commensal E. coli Proteins Activate Host Satiety Pathways following Nutrient - Induced Bacterial Growth ».

Read more

CURRENT MEDICINAL CHEMISTRY (2017).

Fetissov, S. O., R. Legrand, and N. Lucas.

« Bacterial Protein Mimetic of Peptide Hormone as a New Class of Protein - Based Drugs ».

Read more

Press

RELEASES

04th April 2017

TargEDys extends Series A and appoints new Board Members.

Read more

9th March 2017

Bpifrance soutient TargEDys et lui octroie une aide pour le développement à l’innovation de 1,1 million d’euros.

Read more

18th July 2016

TargEDys, laureate of the International Innovation Contest (CMI)

Read more

27th June 2016

TargEDys and Inserm Transfert on behalf of Rouen Normandy University and Rouen University Hospital (CHU) sign an exclusive international licensing agreement on a patent portfolio in microbiome-based research.

Read more

14th April 2016

TargEDys develops new microbiome -based solutions for appetite regulation and announces a €5.8M international round of financing to demonstrate product clinical efficacy.

Read more

Our

INVESTORS

TargEDys has completed Series A funding of 10.6 M€ and will begin Series B in 2020.

ABOUT OUR
INVESTORS

NCI is an investment company operating in Normandy and in Ile de France. NCI strives to create sustainable value within its portfolio companies by reconciling finance, economic development and social welfare.

For more details

Pontifax is a venture capital firm focusing on groundbreaking innovations in the life sciences arena. Founded in 2004 and with $350M under management, Pontifax seeks transformative, innovative healthcare opportunities at all development stages.

For more details

With over €660m in assets under management, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies and Life sciences.

For more details

Zaluvida an integrated global life science group lead out of it’s corporate offices in Switzerland. By using unique bioactive compounds extracted from nature, we pioneer in tackling some of the world’s big challenges like obesity, antibiotic resistance and livestock emissions.

For more details

Our

Team

The main strengths of the team are a very strong Board and Development Committee and CEO with valuable experience running biotech companies, marketing, research and launch products both medical and nutraceutical.

Pierre Déchelotte

Prof, MD, PhD

Founder
Medical Referent

Sergueï Fetissov

Prof, MD, PhD

Founder
Scientific Referent

Grégory Lambert

PhD, Pharm D

CEO and VP R&D

Antonia Trower

BSc

Marketing Manager

Bénédicte Hérate

BA

Office Manager

Clémentine Picolo

Eng

Development
Project Manager

Manon Dominique

MSc

PhD Student

Marie Galmiche

Eng

PhD Student

Nicolas Lucas

PhD

Research Manager

Romain Legrand

PhD

Research Manager

Saïda Azhar

BTS

Lab Technician

Board of Directors

Founder
Medical Referent

Pierre Déchelotte

MD 1990, Gastroenterologist, Rouen – PhD 1992, Paris -Post -doctorant 1993, Hannover. Professor of human Nutrition and Head of Clinical Nutrition, Rouen University Hospital Past-President of European Society for Clinical Nutrition & Metabolism (ESPEN 2010) Original papers : 120 ; h-index 26. Inventor of 8 patents. BWA now TargEDys co-founder.

CEO and VP R&D

Grégory Lambert

Grégory LAMBERT's career has been split between biotech and pharmaceutical companies, in roles such as VP of R&D and General Manager of Novagali Pharma (now Santen) and CSO at Septodont. His responsibilities covered management of IP and business development activities, innovation and CMC as well as pre-clinical and clinical development in Europe and North America. Gregory is an inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he drove the development of several pharmaceutical products from the laboratory to market authorisations. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations.

Chairman of the Board

PHILIPPE  LAVIELLE

Philippe LAVIELLE is an accomplished entrepreneur. He is currently Chairman and CEO of Fermentalg, a French industrial biotech company specialising in microalgae derived products. Until July 2014 Philippe was President and CEO of Virdia Inc., a biotech company producing carbohydrates from cellulosic biomass. His teams developed one of the world’s most advanced ligno-cellulosic bio-refinery platforms. Prior to joining Virdia, Philippe was Executive Vice President of Genencor Inc., the US based world leader in industrial biotechnology in renewable fuels and bio-chemicals. Philippe is also a Board member of Clara Foods Inc., a US company working towards creating the world’s first animal-free egg white.

Independant Board Member

DANILO  CASADEI-MASSARI

Danilo has extensive experience as a senior pharmaceutical executive and as a highly successful serial entrepreneur. Most recently he was a founder and President of CM&D Pharma Ltd, a medical foods company he founded in 2007 and sold to Nestle Health Science in 2011. He is currently a Director on the boards of companies based in the USA, Italy, Ireland, Finland and France as well as a Cofounder in some of them. Danilo is an expert in start-ups and co-ventures in the pharmaceutical sector.

President & CEO, Seventure Partners

ISABELLE DE CRÉMOUX

Isabelle is President and CEO of Seventure Partners and manages the Life Sciences team. She brings 25 years of international experience in life sciences business development and finance. Isabelle leads the life sciences team and makes direct investments, mainly in France and Scandinavia and in the US/Canada with a focus on biotech, nutrition, personalised medicine and especially microbiome. Isabelle’s track record includes Santaris (sold to Roche for $450 millions in august 2014), Argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience, Maat Pharma and TargEDys.

Venture Partner, Seventure Partners

ERIC DE LA FORTELLE

Eric is Venture Partner with Seventure Partners, a Paris-based venture investor investing broadly in life sciences, with a specific focus on the human microbiome. Seventure closed the first microbiome fund worldwide, called Health for Life, in December 2015. Formerly, Eric was the CEO of a Swiss Biotech company and has led Roche’s global function of External Research and Technologies. Eric is a scientist by training (protein structure determination by X-ray crystallography). He was trained as an engineer and physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, and an MBA (honors) from INSEAD.

Analyst, Pontifax

OHAD  HAMMER

Ohad is an analyst at Pontifax, a healthcare-dedicated VC based in Israel. He joined Pontifax in 2009 and focuses on early stage biotechnology investments with an emphasis on oncology and rare diseases. Ohad's work primarily revolves around evaluating new investment opportunities and company creation. He holds a M.S. in biology from Tel-Aviv University.

Chief Scientific Officer, Zaluvida Group

MATTHIAS  MILLER

Matthias's expertise lies in bringing a product concept through to developement and clinical trials. Prior to his appointement as Chief Scientific Officer at Zaluvida, Matthias was the MD and COO of analyze & realize GmbH, a Berlin based life science compagny, wich is now part of Zaluvida Group. From 1987 till 2006, he worked in managing positions with German compagnies operating in the field of natural health products.

Investment analyst, NCI

LAURIE  PÉRIÉ

Laurie is an investment analyst at NCI, a Normandy -based structure which invests in companies operating in Normandy and in Paris. NCI accompanied more than 130 firms at different stages (VC, LBO, growth capital) and in diverse industries. With a double-digit growth track record, and €180M in managed assets (entrusted by public and private institutional investors), NCI conciliates finance and economic development. Laurie graduated from Rouen Business School in Corporate Finance and passed all the three levels of the CFA Program.

CEO, Zaluvida Group

CHRISTOPH  STAEUBLE

Chris is a proven business leader with a track record of delivering exceptional business results in FMCG and SMCG industries. He spent the initial 17 years of his career with P&G, last as Managing Director Health Care, before joining Omega Pharma as Chief Operating Officer in 2010. He led Omega Pharma into the TOP of the European OTC industry then joined Zaluvida on July 1, 2016.

Contact

Us

WHERE TO FIND US?

Office
Zone d'activités Nativelle
Bat 4bis
1 Chemin de Saulxier
91160 Longjumeau
France
Tel: +33 1 72 48 84 57

R&D Laboratories
Faculté de Médecine et de Pharmacie
Bâtiment Recherche - 4ème étage
22 boulevard Gambetta
76183 Rouen
France

Download detailed access plan including car and public transportation Access Plan TargEDys.pdf
Document Adobe Acrobat [198.6 KB]